black seed oil in treatment of osteoarthritis

Conditions: Osteo Arthritis Knee

Summary: osteoarthritis is a continual illness of joints. we aim to investigate the effect of nigella sativa oil in comparison with placebo on the reduction of osteoarthritis pain. this study is a double-blinded, randomized, controlled trial study, conducting in vali-e-asr hospital in 2019, in birjand, on patients with mild osteoarthritis. the western ontario and mcmaster universities osteoarthritis index is applied to score the functional status of participants' joints.

this study was a randomized controlled trial. regarding to the inclusion criteria, 110 osteoarthritis patients were included in this study based on clinical signs, physical examination and radiological signs. in the next step, a fully explanation was given to the participants around the conditions of conducting the research, and then the informed consent were collected. subsequently, patients were randomly divided into two groups of recipients; black seed soft gel capsules (intervention) and placebo equally in accordance with demographic information. furthermore, the two groups were randomly classified regarding to age, consequently the study population was divided into subgroups of categorized ages. thereafter, an equal number of each subgroup was randomly selected and divided into two groups to take black seed and placebo. therefore, the two groups were similar, but the exact membership of individuals in the groups were random. due to the higher prevalence of osteoarthritis among women in the community, the number of female cases were higher. it should be noted that the experimenters as well as patients did not know who was receiving a particular treatment (double-blinded study). prior to commencing the study, participants were asked to take a regular 48-day course of anti-inflammatory therapy. the cases in the intervention group took 700 mg of black seed soft gel capsule once a day from gorgan essential oil pharmaceutical company, and the control group were treated by placebo capsules in the same-color and shape of the drug, with a taste of rice bran. moreover, questionnaires were filled to record demographic information of both groups including age, sex, history medication and diet. the condition of participants were evaluated twice before the treatment and 48 days after the onset of black seed. at the end of each period, joint pain scores, the range of activity, and the dryness of the joints of all patients were assessed, and their mean were measured. data collection tools: scoring the functional status of individuals' joints were evaluated by applying western ontario and mcmaster universities osteoarthritis index (womac)\[2\]. the womac questionnaire was published in the 1908s to assess osteoarthritis of hip and knee, which is a standard criterion for assessing the health status of patients' self-reported activity. three criteria should be measured ranging between zero to 4 for each question, by the end of each evaluation period: reduce pain is identified based on the mean for the first 5 womac questions (from no pain to severe pain), the 6th and 7th questions were specified for joint dryness (from no dryness to severe limitation),and joint movement is determined based on the average of questions 0 to 24 (from no problem to severe limit).

Eligibility criteria:
inclusion criteria: * unilateral or bilateral involvement of one or more joints for over 4 months, * ability to walk * ability to stay throughout the study period * no history of underlying inflammatory disease (arthropathy / rheumatoid arthritis), * absence of diabetes, * no history of allergy to black seed * absence of hyperuricemia (\<338 umol/l) or history of gout, * absence of recent injury and trauma to the joint with osteoarthritis, * absence of intra articular injection of corticosteroids in the last 4 months, * lack of sensitivity to nsaids, * no underlying liver and kidney disease or history of peptic ulcer or gastrointestinal bleeding, congestive heart failure, hypertension, and hyperkalemia , * no fever * absence of obvious complete blood count disorders, coagulopathy, hematologic or neurological disorders , * no alcohol consumption exclusion criteria: * pregnancy, * breast feeding, * pregnancy-related decision * obesity (bmi\> 30 kg /m2).